Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds

Molecular Nutrition and Food Research

Volumn 58, Issue 1, 2014, Pages 147-171

  Pan, Min Hsiung ^a,b   Lai, Ching Shu ^a   Tsai, Mei Ling ^c   Ho, Chi Tang ^d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL KAOHSIUNG UNIVERSITY OF APPLIED SCIENCES   (Taiwan)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Chemoprevention; Dietary natural compounds; Nonalcoholic fatty liver disease

Indexed keywords

ADIPOCYTOKINE; CAROTENOID; CURCUMIN; FLAVONOL DERIVATIVE; OMEGA 3 FATTY ACID; POLYPHENOL; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; CHEMISTRY; CHEMOPROPHYLAXIS; DIETARY NATURAL COMPOUNDS; FATTY LIVER; HUMAN; INSULIN RESISTANCE; METABOLISM; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW;

CHEMOPREVENTION; DIETARY NATURAL COMPOUNDS; NONALCOHOLIC FATTY LIVER DISEASE;

ADIPOKINES; ANIMALS; CAROTENOIDS; CURCUMIN; FATTY ACIDS, OMEGA-3; FATTY LIVER; FLAVONOLS; HUMANS; INSULIN RESISTANCE; OBESITY; OXIDATIVE STRESS; POLYPHENOLS; STILBENES;

EID: 84891402274     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300522     Document Type: Review

References (256)

1. Angulo, P., Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221-1231.
2. Shifflet, A., Wu, G. Y., Non-alcoholic steatohepatitis: an overview. J. Formos. Med. Assoc. 2009, 108, 4-12.
3. Neuschwander-Tetri, B. A., Clark, J. M., Bass, N. M., Van Natta, M. L. et al., Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010, 52, 913-924.
4. Vernon, G., Baranova, A., Younossi, Z. M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34, 274-285.
5. Bhala, N., Jouness, R. I., Bugianesi, E., Epidemiology and natural history of patients with NAFLD. Curr. Pharm. Des. 2013, 19, 5169-5176.
6. Levene, A. P., Goldin, R. D., The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012, 61, 141-152.
7. Fan, J. G., Zhu, J., Li, X. J., Chen, L. et al., Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005, 43, 508-514.
8. Jimba, S., Nakagami, T., Takahashi, M., Wakamatsu, T. et al., Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 2005, 22, 1141-1145.
9. Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C. et al., Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42, 44-52.
10. Kwon, Y. M., Oh, S. W., Hwang, S. S., Lee, C. et al., Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am. J. Gastroenterol. 2012, 107, 1852-1858.
11. Bellentani, S., Scaglioni, F., Marino, M., Bedogni, G., Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010, 28, 155-161.
12. McCullough, A. J., The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 2004, 8, 521-533.
13. Ekstedt, M., Franzen, L. E., Mathiesen, U. L., Thorelius, L. et al., Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44, 865-873.
14. Day, C. P., James, O. F., Steatohepatitis: a tale of two "hits"? Gastroenterology 1998, 114, 842-845.
15. Tilg, H., Moschen, A. R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52, 1836-1846.
16. Reaven, G., Abbasi, F., McLaughlin, T., Obesity, insulin resistance, and cardiovascular disease. Recent Prog. Horm. Res. 2004, 59, 207-223.
17. Ong, J. P., Elariny, H., Collantes, R., Younoszai, A. et al., Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes. Surg. 2005, 15, 310-315.
18. Colicchio, P., Tarantino, G., del, G. F., Sorrentino, P. et al., Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann. Nutr. Metab. 2005, 49, 289-295.
19. Liew, P. L., Lee, W. J., Wang, W., Lee, Y. C. et al., Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes. Surg. 2008, 18, 847-853.
20. Huang, H. L., Lin, W. Y., Lee, L. T., Wang, H. H. et al., Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes. Surg. 2007, 17, 1457-1463.
21. Dolce, C. J., Russo, M., Keller, J. E., Buckingham, J. et al., Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg. Obes. Relat. Dis. 2009, 5, 323-328.
22. Harnois, F., Msika, S., Sabate, J. M., Mechler, C. et al., Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes. Surg. 2006, 16, 183-188.
23. Gholam, P. M., Flancbaum, L., Machan, J. T., Charney, D. A. et al., Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 2007, 102, 399-408.
24. Yoo, J., Lee, S., Kim, K., Yoo, S. et al., Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children. Diabetes Res. Clin. Pract. 2008, 81, 321-326.
25. Patton, H. M., Yates, K., Unalp-Arida, A., Behling, C. A. et al., Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am. J. Gastroenterol. 2010, 105, 2093-2102.
26. Galic, S., Oakhill, J. S., Steinberg, G. R., Adipose tissue as an endocrine organ. Mol. Cell Endocrinol. 2010, 316, 129-139.
27. Choi, S. M., Tucker, D. F., Gross, D. N., Easton, R. M. et al., Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol. Cell Biol. 2010, 30, 5009-5020.
28. Stralfors, P., Honnor, R. C., Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. Eur. J. Biochem. 1989, 182, 379-385.
29. Lam, T. K., Yoshii, H., Haber, C. A., Bogdanovic, E. et al., Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am. J. Physiol. Endocrinol. Metab. 2002, 283, E682-E691.
30. Boden, G., Cheung, P., Stein, T. P., Kresge, K. et al., FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am. J. Physiol. Endocrinol. Metab. 2002, 283, E12-E19.
31. Boden, G., Chen, X., Ruiz, J., White, J. V. et al., Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. 1994, 93, 2438-2446.
32. Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J. et al., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115, 1343-1351.
33. Kissebah, A. H., Krakower, G. R., Regional adiposity and morbidity. Physiol. Rev. 1994, 74, 761-811.
34. van der, K. K., Leenen, R., Seidell, J. C., Deurenberg, P. et al., Abdominal diameters as indicators of visceral fat: comparison between magnetic resonance imaging and anthropometry. Br. J. Nutr. 1993, 70, 47-58.
35. Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D. et al., Splanchnic lipolysis in human obesity. J. Clin. Invest. 2004, 113, 1582-1588.
36. van der, P. D., Milner, K. L., Hui, J., Hodge, A. et al., Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48, 449-457.
37. Ibrahim, M. M., Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 2010, 11, 11-18.
38. Preis, S. R., Massaro, J. M., Robins, S. J., Hoffmann, U. et al., Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) 2010, 18, 2191-2198.
39. Guilherme, A., Virbasius, J. V., Puri, V., Czech, M. P., Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9, 367-377.
40. Hotamisligil, G. S., Shargill, N. S., Spiegelman, B. M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259, 87-91.
41. Uysal, K. T., Wiesbrock, S. M., Marino, M. W., Hotamisligil, G. S., Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389, 610-614.
42. Haukeland, J. W., Damas, J. K., Konopski, Z., Loberg, E. M. et al., Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006, 44, 1167-1174.
43. Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G. et al., Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004, 40, 46-54.
44. Crespo, J., Cayon, A., Fernandez-Gil, P., Hernandez-Guerra, M. et al., Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34, 1158-1163.
45. Li, Z., Yang, S., Lin, H., Huang, J. et al., Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37, 343-350.
46. Van Wagner, L. B., Koppe, S. W., Brunt, E. M., Gottstein, J. et al., Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann. Hepatol. 2011, 10, 277-286.
47. Yalniz, M., Bahcecioglu, I. H., Kuzu, N., Celebi, S. et al., Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet. Dig. Dis. Sci. 2007, 52, 2380-2386.
48. Feldstein, A. E., Werneburg, N. W., Canbay, A., Guicciardi, M. E. et al., Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40, 185-194.
49. Chakraborty, C., Biochemical and molecular basis of insulin resistance. Curr. Protein Pept. Sci. 2006, 7, 113-121.
50. Feingold, K. R., Soued, M., Serio, M. K., Adi, S. et al., The effect of diet on tumor necrosis factor stimulation of hepatic lipogenesis. Metabolism 1990, 39, 623-632.
51. Moschen, A. R., Molnar, C., Geiger, S., Graziadei, I. et al., Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010, 59, 1259-1264.
52. Fernandez-Real, J. M., Vayreda, M., Richart, C., Gutierrez, C. et al., Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab. 2001, 86, 1154-1159.
53. Wang, X., Bao, W., Liu, J., Ouyang, Y. Y. et al., Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013, 36, 166-175.
54. Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E. et al., Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56, 1010-1013.
55. Senn, J. J., Klover, P. J., Nowak, I. A., Zimmers, T. A. et al., Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278, 13740-13746.
56. Sabio, G., Das, M., Mora, A., Zhang, Z. et al., A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322, 1539-1543.
57. Friedman, J. M., Halaas, J. L., Leptin and the regulation of body weight in mammals. Nature 1998, 395, 763-770.
58. Lam, Q. L., Lu, L., Role of leptin in immunity. Cell. Mol. Immunol. 2007, 4, 1-13.
59. Huang, X. D., Fan, Y., Zhang, H., Wang, P. et al., Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J. Gastroenterol. 2008, 14, 2888-2893.
60. Lemoine, M., Ratziu, V., Kim, M., Maachi, M. et al., Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009, 29, 1431-1438.
61. Chitturi, S., Farrell, G., Frost, L., Kriketos, A. et al., Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002, 36, 403-409.
62. Huang, X. D., Fan, Y., Zhang, H., Wang, P. et al., Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J. Gastroenterol. 2008, 14, 2888-2893.
63. Canbakan, B., Tahan, V., Balci, H., Hatemi, I. et al., Leptin in nonalcoholic fatty liver disease. Ann. Hepatol. 2008, 7, 249-254.
64. Anania, F. A., Leptin, liver, and obese mice-fibrosis in the fat lane. Hepatology 2002, 36, 246-248.
65. Ikejima, K., Takei, Y., Honda, H., Hirose, M. et al., Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122, 1399-1410.
66. Leclercq, I. A., Farrell, G. C., Schriemer, R., Robertson, G. R., Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 2002, 37, 206-213.
67. Wang, J., Leclercq, I., Brymora, J. M., Xu, N. et al., Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009, 137, 713-723.
68. Targher, G., Bertolini, L., Scala, L., Poli, F. et al., Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin. Endocrinol. (Oxf.) 2004, 61, 700-703.
69. Louthan, M. V., Barve, S., McClain, C. J., Joshi-Barve, S., Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J. Pediatr. 2005, 147, 835-838.
70. Buechler, C., Wanninger, J., Neumeier, M., Adiponectin, a key adipokine in obesity related liver diseases. World J. Gastroenterol. 2011, 17, 2801-2811.
71. Tilg, H., The role of cytokines in non-alcoholic fatty liver disease. Dig. Dis. 2010, 28, 179-185.
72. Xu, A., Wang, Y., Keshaw, H., Xu, L. Y. et al., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003, 112, 91-100.
73. Awazawa, M., Ueki, K., Inabe, K., Yamauchi, T. et al., Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem. Biophys. Res. Commun. 2009, 382, 51-56.
74. Saltiel, A. R., Kahn, C. R., Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414, 799-806.
75. Taniguchi, C. M., Emanuelli, B., Kahn, C. R., Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7, 85-96.
76. Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J. et al., Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003, 423, 550-555.
77. Chiang, S. H., Baumann, C. A., Kanzaki, M., Thurmond, D. C. et al., Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 2001, 410, 944-948.
78. Postic, C., Girard, J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 2008, 118, 829-838.
79. Kahn, S. E., The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46, 3-19.
80. Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P. et al., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40, 1387-1395.
81. Targher, G., Bertolini, L., Padovani, R., Rodella, S. et al., Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30, 1212-1218.
82. Porepa, L., Ray, J. G., Sanchez-Romeu, P., Booth, G. L., Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. Can. Med. Assoc. J. 2010, 182, E526-E531.
83. Prashanth, M., Ganesh, H. K., Vima, M. V., John, M. et al., Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J. Assoc. Physicians India 2009, 57, 205-210.
84. Adams, L. A., Harmsen, S., St Sauver, J. L., Charatcharoenwitthaya, P. et al., Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. 2010, 105, 1567-1573.
85. Voshol, P. J., Haemmerle, G., Ouwens, D. M., Zimmermann, R. et al., Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. Endocrinology 2003, 144, 3456-3462.
86. Smith, B. W., Adams, L. A., Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 2011, 7, 456-465.
87. Tarantino, G., Caputi, A., JNKs, insulin resistance and inflammation: a possible link between NAFLD and coronary artery disease. World J. Gastroenterol. 2011, 17, 3785-3794.
88. Schwarz, J. M., Linfoot, P., Dare, D., Aghajanian, K., Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am. J. Clin. Nutr. 2003, 77, 43-50.
89. bu-Elheiga, L., Matzuk, M. M., bo-Hashema, K. A., Wakil, S. J., Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001, 291, 2613-2616.
90. An, J., Muoio, D. M., Shiota, M., Fujimoto, Y. et al., Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 2004, 10, 268-274.
91. Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M. et al., Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125, 437-443.
92. Feldstein, A. E., Werneburg, N. W., Li, Z., Bronk, S. F. et al., Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G1339-G1346.
93. Li, Z., Berk, M., McIntyre, T. M., Gores, G. J. et al., The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008, 47, 1495-1503.
94. Li, Z. Z., Berk, M., McIntyre, T. M., Feldstein, A. E., Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem. 2009, 284, 5637-5644.
95. Malhi, H., Bronk, S. F., Werneburg, N. W., Gores, G. J., Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 2006, 281, 12093-12101.
96. Barreyro, F. J., Kobayashi, S., Bronk, S. F., Werneburg, N. W. et al., Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J. Biol. Chem. 2007, 282, 27141-27154.
97. Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M. et al., Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125, 437-443.
98. Feldstein, A. E., Canbay, A., Guicciardi, M. E., Higuchi, H. et al., Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 2003, 39, 978-983.
99. Inoue, Y., Asanuma, T., Smith, N., Saunders, D. et al., Modulation of Fas-FasL related apoptosis by PBN in the early phases of choline deficient diet-mediated hepatocarcinogenesis in rats. Free Radic. Res. 2007, 41, 972-980.
100. Malhi, H., Barreyro, F. J., Isomoto, H., Bronk, S. F. et al., Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007, 56, 1124-1131.
101. Volkmann, X., Fischer, U., Bahr, M. J., Ott, M. et al., Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007, 46, 1498-1508.
102. Cazanave, S. C., Mott, J. L., Bronk, S. F., Werneburg, N. W. et al., Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J. Biol. Chem. 2011, 286, 39336-39348.
103. Wei, Y., Wang, D., Topczewski, F., Pagliassotti, M. J., Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E275-E281.
104. Wang, D., Wei, Y., Pagliassotti, M. J., Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006, 147, 943-951.
105. Puri, P., Mirshahi, F., Cheung, O., Natarajan, R. et al., Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134, 568-576.
106. Rinella, M. E., Siddiqui, M. S., Gardikiotes, K., Gottstein, J. et al., Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology 2011, 54, 1600-1609.
107. Hotamisligil, G. S., Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140, 900-917.
108. Seki, S., Kitada, T., Sakaguchi, H., Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol. Res. 2005, 33, 132-134.
109. Madan, K., Bhardwaj, P., Thareja, S., Gupta, S. D. et al., Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J. Clin. Gastroenterol. 2006, 40, 930-935.
110. Weltman, M. D., Farrell, G. C., Liddle, C., Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996, 111, 1645-1653.
111. Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M. et al., Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27, 128-133.
112. Reddy, J. K., Hashimoto, T., Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 2001, 21, 193-230.
113. Caldwell, S. H., Swerdlow, R. H., Khan, E. M., Iezzoni, J. C. et al., Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 1999, 31, 430-434.
114. Perez-Carreras, M., Del, H. P., Martin, M. A., Rubio, J. C. et al., Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003, 38, 999-1007.
115. Sanchez-Alcazar, J. A., Schneider, E., Martinez, M. A., Carmona, P. et al., Tumor necrosis factor-alpha increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J. Biol. Chem. 2000, 275, 13353-13361.
116. Higuchi, M., Proske, R. J., Yeh, E. T., Inhibition of mitochondrial respiratory chain complex I by TNF results in cytochrome c release, membrane permeability transition, and apoptosis. Oncogene 1998, 17, 2515-2524.
117. Pan, M., Cederbaum, A. I., Zhang, Y. L., Ginsberg, H. N. et al., Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J. Clin. Invest. 2004, 113, 1277-1287.
118. Perlemuter, G., vit-Spraul, A., Cosson, C., Conti, M. et al., Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. Liver Int. 2005, 25, 946-953.
119. Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A. et al., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999, 94, 2467-2474.
120. Chalasani, N., Wilson, L., Kleiner, D. E., Cummings, O. W. et al., Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J. Hepatol. 2008, 48, 829-834.
121. Schwabe, R. F., Uchinami, H., Qian, T., Bennett, B. L. et al., Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes. FASEB J. 2004, 18, 720-722.
122. Dela, P. A., Leclercq, I., Field, J., George, J. et al., NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005, 129, 1663-1674.
123. Schattenberg, J. M., Singh, R., Wang, Y., Lefkowitch, J. H. et al., JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43, 163-172.
124. Csak, T., Ganz, M., Pespisa, J., Kodys, K. et al., Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54, 133-144.
125. Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R. et al., Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008, 103, 1372-1379.
126. Yamaguchi, K., Itoh, Y., Yokomizo, C., Nishimura, T. et al., Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab. Invest. 2010, 90, 1169-1178.
127. Dooley, S., ten, D. P., TGF-beta in progression of liver disease. Cell Tissue Res. 2012, 347, 245-256.
128. Choudhury, J., Mirshahi, F., Murthy, K. S., Yager, D. R. et al., Physiologic concentrations of leptin increase collagen production by non-immortalized human hepatic stellate cells. Metabolism 2006, 55, 1317-1322.
129. George, J., Pera, N., Phung, N., Leclercq, I. et al., Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 2003, 39, 756-764.
130. Teufelhofer, O., Parzefall, W., Kainzbauer, E., Ferk, F. et al., Superoxide generation from Kupffer cells contributes to hepatocarcinogenesis: studies on NADPH oxidase knockout mice. Carcinogenesis 2005, 26, 319-329.
131. Gornicka, A., Morris-Stiff, G., Thapaliya, S., Papouchado, B. G. et al., Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid. Redox Signal. 2011, 15, 437-445.
132. Musso, G., Cassader, M., Rosina, F., Gambino, R., Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55, 885-904.
133. Kim, M. S., Kung, S., Grewal, T., Roufogalis, B. D., Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD). Curr. Pharm. Biotechnol. 2012, 13, 278-291.
134. Musso, G., Gambino, R., Cassader, M., Pagano, G., A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52, 79-104.
135. Nissen, S. E., Wolski, K., Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 2010, 170, 1191-1201.
136. Bahcecioglu, I. H., Kuzu, N., Metin, K., Ozercan, I. H. et al., Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet. Vet. Med. Int. 2010, 2010, 1-8.
137. Wang, Y., Ausman, L. M., Greenberg, A. S., Russell, R. M. et al., Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int. J. Cancer 2010, 126, 1788-1796.
138. Choi, S. K., Seo, J. S., Lycopene supplementation suppresses oxidative stress induced by a high fat diet in gerbils. Nutr. Res. Pract. 2013, 7, 26-33.
139. Ahn, J., Lee, H., Jung, C. H., Ha, T., Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol. Nutr. Food Res. 2012, 56, 1665-1674.
140. Gugger, E. T., Bierer, T. L., Henze, T. M., White, W. S. et al., Beta-carotene uptake and tissue distribution in ferrets (Mustela putorius furo). J. Nutr. 1992, 122, 115-119.
141. Kameji, H., Mochizuki, K., Miyoshi, N., Goda, T., beta-Carotene accumulation in 3T3-L1 adipocytes inhibits the elevation of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-alpha. Nutrition 2010, 26, 1151-1156.
142. Sangeetha, R. K., Bhaskar, N., Baskaran, V., Comparative effects of beta-carotene and fucoxanthin on retinol deficiency induced oxidative stress in rats. Mol. Cell. Biochem. 2009, 331, 59-67.
143. Kim, J. E., Clark, R. M., Park, Y., Lee, J. et al., Lutein decreases oxidative stress and inflammation in liver and eyes of guinea pigs fed a hypercholesterolemic diet. Nutr. Res. Pract. 2012, 6, 113-119.
144. Woo, M. N., Jeon, S. M., Shin, Y. C., Lee, M. K. et al., Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. Mol. Nutr. Food Res. 2009, 53, 1603-1611.
145. Maeda, H., Hosokawa, M., Sashima, T., Murakami-Funayama, K. et al., Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model. Mol. Med. Rep. 2009, 2, 897-902.
146. Woo, M. N., Jeon, S. M., Kim, H. J., Lee, M. K. et al., Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N mice. Chem. Biol. Interact. 2010, 186, 316-322.
147. Hosokawa, M., Miyashita, T., Nishikawa, S., Emi, S. et al., Fucoxanthin regulates adipocytokine mRNA expression in white adipose tissue of diabetic/obese KK-Ay mice. Arch. Biochem. Biophys. 2010, 504, 17-25.
148. Beppu, F., Hosokawa, M., Yim, M. J., Shinoda, T. et al., Down-regulation of hepatic stearoyl-CoA desaturase-1 expression by fucoxanthin via leptin signaling in diabetic/obese KK-A(y) mice. Lipids 2013, 48, 449-455.
149. Zhu, F. S., Liu, S., Chen, X. M., Huang, Z. G. et al., Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J. Gastroenterol. 2008, 14, 6395-6400.
150. Janczyk, W., Socha, P., Lebensztejn, D., Wierzbicka, A. et al., Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr. 2013, 13, 85.
151. Masterton, G. S., Plevris, J. N., Hayes, P. C., Review article: omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2010, 31, 679-692.
152. Kuda, O., Jelenik, T., Jilkova, Z., Flachs, P. et al., n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia 2009, 52, 941-951.
153. Lamaziere, A., Wolf, C., Barbe, U., Bausero, P. et al., Lipidomics of hepatic lipogenesis inhibition by omega 3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 2013, 88, 149-154.
154. Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E. et al., Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2008, 42, 413-418.
155. Oya, J., Nakagami, T., Sasaki, S., Jimba, S. et al., Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. Eur. J. Clin. Nutr. 2010, 64, 1179-1185.
156. Nemoto, N., Suzuki, S., Kikuchi, H., Okabe, H. et al., Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. In Vivo 2009, 23, 685-689.
157. Shiba, S., Tsunoda, N., Wakutsu, M., Muraki, E. et al., Regulation of lipid metabolism by palmitoleate and eicosapentaenoic acid (EPA) in mice fed a high-fat diet. Biosci. Biotechnol. Biochem. 2011, 75, 2401-2403.
158. Kajikawa, S., Harada, T., Kawashima, A., Imada, K. et al., Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet. Biochim. Biophys. Acta 2009, 1791, 281-288.
159. Matsumoto, T., Terai, S., Oishi, T., Kuwashiro, S. et al., Medaka as a model for human nonalcoholic steatohepatitis. Dis. Model. Mech. 2010, 3, 431-440.
160. Varela-Rey, M., Embade, N., Ariz, U., Lu, S. C. et al., Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int. J. Biochem. Cell Biol. 2009, 41, 969-976.
161. Kajikawa, S., Imada, K., Takeuchi, T., Shimizu, Y. et al., Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet. Dig. Dis. Sci. 2011, 56, 1065-1074.
162. Kajikawa, S., Harada, T., Kawashima, A., Imada, K. et al., Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats. Dig. Dis. Sci. 2010, 55, 631-641.
163. Ishii, H., Horie, Y., Ohshima, S., Anezaki, Y. et al., Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J. Hepatol. 2009, 50, 562-571.
164. Nanthirudjanar, T., Furumoto, H., Hirata, T., Sugawara, T., Oxidized eicosapentaenoic acids more potently reduce LXRalpha-induced cellular triacylglycerol via suppression of SREBP-1c, PGC-1beta and GPA than its intact form. Lipids Health Dis. 2013, 12, 73.
165. Nobili, V., Bedogni, G., Alisi, A., Pietrobattista, A. et al., Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch. Dis. Child. 2011, 96, 350-353.
166. Nobili, V., Alisi, A., Della, C. C., Rise, P. et al., Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr. Metab. Cardiovasc. Dis. 2012, in press.
167. Takayama, F., Nakamoto, K., Totani, N., Yamanushi, T. et al., Effects of docosahexaenoic acid in an experimental rat model of nonalcoholic steatohepatitis. J. Oleo. Sci. 2010, 59, 407-414.
168. Poudyal, H., Panchal, S. K., Ward, L. C., Brown, L., Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. J. Nutr. Biochem. 2013, 24, 1041-1052.
169. Tang, X., Li, Z. J., Xu, J., Xue, Y. et al., Short term effects of different omega-3 fatty acid formulation on lipid metabolism in mice fed high or low fat diet. Lipids Health Dis. 2012, 11, 70.
170. Depner, C. M., Philbrick, K. A., Jump, D. B., Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J. Nutr. 2013, 143, 315-323.
171. Kim, H. J., Lee, K. T., Park, Y. B., Jeon, S. M. et al., Dietary docosahexaenoic acid-rich diacylglycerols ameliorate hepatic steatosis and alter hepatic gene expressions in C57BL/6J-Lep(ob/ob) mice. Mol. Nutr. Food Res. 2008, 52, 965-973.
172. Fedor, D. M., Adkins, Y., Mackey, B. E., Kelley, D. S., Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation. Metab. Syndr. Relat. Disord. 2012, 10, 175-180.
173. Vemuri, M., Kelley, D. S., Mackey, B. E., Rasooly, R. et al., Docosahexaenoic acid (DHA) but not eicosapentaenoic acid (EPA) prevents trans-10, cis-12 conjugated linoleic acid (CLA)-induced insulin resistance in mice. Metab. Syndr.Relat. Disord. 2007, 5, 315-322.
174. Luo, X., Yang, Y., Shen, T., Tang, X. et al., Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells. Nutr. Metab. (Lond.) 2012, 9, 34.
175. Tsuzuki, T., Kawakami, Y., Suzuki, Y., Abe, R. et al., Intake of conjugated eicosapentaenoic acid suppresses lipid accumulation in liver and epididymal adipose tissue in rats. Lipids 2005, 40, 1117-1123.
176. Sun, C., Wei, Z. W., Li, Y., DHA regulates lipogenesis and lipolysis genes in mice adipose and liver. Mol. Biol. Rep. 2011, 38, 731-737.
177. Gladine, C., Roy, N. C., Rigaudiere, J. P., Laillet, B. et al., Increasing intake of long-chain n-3 PUFA enhances lipoperoxidation and modulates hepatic gene expression in a dose-dependent manner. Br. J. Nutr. 2011, 1-20.
178. Ono, M., Fujimori, K., Antiadipogenic effect of dietary apigenin through activation of AMPK in 3T3-L1 cells. J. Agric. Food Chem. 2011, 59, 13346-13352.
179. Liu, J. F., Ma, Y., Wang, Y., Du, Z. Y. et al., Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother. Res. 2011, 25, 588-596.
180. Kunimasa, K., Kuranuki, S., Matsuura, N., Iwasaki, N. et al., Identification of nobiletin, a polymethoxyflavonoid, as an enhancer of adiponectin secretion. Bioorg. Med. Chem. Lett. 2009, 19, 2062-2064.
181. Lee, Y. S., Cha, B. Y., Saito, K., Yamakawa, H. et al., Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem. Pharmacol. 2010, 79, 1674-1683.
182. Lee, Y. S., Cha, B. Y., Choi, S. S., Choi, B. K. et al., Nobiletin improves obesity and insulin resistance in high-fat diet-induced obese mice. J. Nutr. Biochem. 2013, 24, 156-162.
183. Miyata, Y., Tanaka, H., Shimada, A., Sato, T. et al., Regulation of adipocytokine secretion and adipocyte hypertrophy by polymethoxyflavonoids, nobiletin and tangeretin. Life Sci. 2011, 88, 613-618.
184. Pu, P., Wang, X. A., Salim, M., Zhu, L. H. et al., Baicalein, a natural product, selectively activating AMPKalpha(2) and ameliorates metabolic disorder in diet-induced mice. Mol. Cell. Endocrinol. 2012, 362, 128-138.
185. Panchal, S. K., Poudyal, H., Brown, L., Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J. Nutr. 2012, 142, 1026-1032.
186. Jung, C. H., Cho, I., Ahn, J., Jeon, T. I. et al., Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother. Res. 2013, 27, 139-143.
187. Hoek-van den Hil E. F., Keijer, J., Bunschoten, A., Vervoort, J. J. et al., Quercetin induces hepatic lipid omega-oxidation and lowers serum lipid levels in mice. PLoS One 2013, 8, e51588.
188. Ying, H. Z., Liu, Y. H., Yu, B., Wang, Z. Y. et al., Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem. Toxicol. 2013, 52, 53-60.
189. Marcolin, E., San-Miguel, B., Vallejo, D., Tieppo, J. et al., Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J. Nutr. 2012, 142, 1821-1828.
190. Marcolin, E., Forgiarini, L. F., Rodrigues, G., Tieppo, J. et al., Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis. Basic Clin. Pharmacol. Toxicol. 2013, 112, 385-391.
191. Jeong, S. M., Kang, M. J., Choi, H. N., Kim, J. H. et al., Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr. Res. Pract. 2012, 6, 201-207.
192. Vidyashankar, S., Sandeep, V. R., Patki, P. S., Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol. In Vitro 2013, 27, 945-953.
193. Crespo, I., Garcia-Mediavilla, M. V., Almar, M., Gonzalez, P. et al., Differential effects of dietary flavonoids on reactive oxygen and nitrogen species generation and changes in antioxidant enzyme expression induced by proinflammatory cytokines in Chang Liver cells. Food Chem. Toxicol. 2008, 46, 1555-1569.
194. Kuzu, N., Bahcecioglu, I. H., Dagli, A. F., Ozercan, I. H. et al., Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J. Gastroenterol. Hepatol. 2008, 23, e465-e470.
195. Bose, M., Lambert, J. D., Ju, J., Reuhl, K. R. et al., The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J. Nutr. 2008, 138, 1677-1683.
196. Chen, Y. K., Cheung, C., Reuhl, K. R., Liu, A. B. et al., Effects of green tea polyphenol (-)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in mice. J. Agric. Food Chem. 2011, 59, 11862-11871.
197. Xiao, J., Ho, C. T., Liong, E. C., Nanji, A. A. et al., Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur. J. Nutr. 2013, in press.
198. Klaus, S., Pultz, S., Thone-Reineke, C., Wolfram, S., Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int. J. Obes. (Lond.) 2005, 29, 615-623.
199. Friedrich, M., Petzke, K. J., Raederstorff, D., Wolfram, S. et al., Acute effects of epigallocatechin gallate from green tea on oxidation and tissue incorporation of dietary lipids in mice fed a high-fat diet. Int. J. Obes. (Lond.) 2012, 36, 735-743.
200. Lin, C. L., Huang, H. C., Lin, J. K., Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J. Lipid Res. 2007, 48, 2334-2343.
201. Luo, X. Y., Takahara, T., Hou, J., Kawai, K. et al., Theaflavin attenuates ischemia-reperfusion injury in a mouse fatty liver model. Biochem. Biophys. Res. Commun. 2012, 417, 287-293.
202. Huong, D. T., Takahashi, Y., Ide, T., Activity and mRNA levels of enzymes involved in hepatic fatty acid oxidation in mice fed citrus flavonoids. Nutrition 2006, 22, 546-552.
203. Mulvihill, E. E., Allister, E. M., Sutherland, B. G., Telford, D. E. et al., Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes 2009, 58, 2198-2210.
204. Assini, J. M., Mulvihill, E. E., Sutherland, B. G., Telford, D. E. et al., Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr(-)/(-) mice. J. Lipid Res. 2013, 54, 711-724.
205. Cha, J. Y., Cho, Y. S., Kim, I., Anno, T. et al., Effect of hesperetin, a citrus flavonoid, on the liver triacylglycerol content and phosphatidate phosphohydrolase activity in orotic acid-fed rats. Plant Foods Hum. Nutr. 2001, 56, 349-358.
206. Iwatsuka, H., Shino, A., Suzuoki, Z., General survey of diabetic features of yellow KK mice. Endocrinol. Jpn. 1970, 17, 23-35.
207. Guo, H., Li, D., Ling, W., Feng, X. et al., Anthocyanin inhibits high glucose-induced hepatic mtGPAT1 activation and prevents fatty acid synthesis through PKCzeta. J. Lipid Res. 2011, 52, 908-922.
208. Guo, H., Xia, M., Zou, T., Ling, W. et al., Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. J. Nutr. Biochem. 2012, 23, 349-360.
209. Zhu, W., Jia, Q., Wang, Y., Zhang, Y. et al., The anthocyanin cyanidin-3-O-beta-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: involvement of a cAMP-PKA-dependent signaling pathway. Free Radic. Biol. Med. 2012, 52, 314-327.
210. Guo, H., Liu, G., Zhong, R., Wang, Y. et al., Cyanidin-3-O-beta-glucoside regulates fatty acid metabolism via an AMP-activated protein kinase-dependent signaling pathway in human HepG2 cells. Lipids Health Dis. 2012, 11, 10.
211. Kim, M. H., Park, J. S., Jung, J. W., Byun, K. W. et al., Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int. J. Obes.(Lond.) 2011, 35, 1019-1030.
212. Crespillo, A., Alonso, M., Vida, M., Pavon, F. J. et al., Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. Br. J. Pharmacol. 2011, 164, 1899-1915.
213. Takahashi, Y., Odbayar, T. O., Ide, T., A comparative analysis of genistein and daidzein in affecting lipid metabolism in rat liver. J. Clin. Biochem. Nutr. 2009, 44, 223-230.
214. Shin, E. S., Cho, S. Y., Lee, E. H., Lee, S. J. et al., Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. Eur. J. Nutr. 2006, 45, 159-164.
215. Kim, S., Shin, H. J., Kim, S. Y., Kim, J. H. et al., Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol. Cell. Endocrinol. 2004, 220, 51-58.
216. Shin, E. S., Lee, H. H., Cho, S. Y., Park, H. W. et al., Genistein downregulates SREBP-1 regulated gene expression by inhibiting site-1 protease expression in HepG2 cells. J. Nutr. 2007, 137, 1127-1131.
217. Kim, M. H., Kang, K. S., Lee, Y. S., The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br. J. Nutr. 2010, 104, 1333-1342.
218. Yalniz, M., Bahcecioglu, I. H., Kuzu, N., Poyrazoglu, O. K. et al., Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J. Gastroenterol. Hepatol. 2007, 22, 2009-2014.
219. Lee, Y. M., Choi, J. S., Kim, M. H., Jung, M. H. et al., Effects of dietary genistein on hepatic lipid metabolism and mitochondrial function in mice fed high-fat diets. Nutrition 2006, 22, 956-964.
220. Huang, C., Qiao, X., Dong, B., Neonatal exposure to genistein ameliorates high-fat diet-induced non-alcoholic steatohepatitis in rats. Br. J. Nutr. 2011, 106, 105-113.
221. Ji, G., Yang, Q., Hao, J., Guo, L. et al., Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int. Immunopharmacol. 2011, 11, 762-768.
222. Mohamed, S. S., Nallasamy, P., Muniyandi, P., Periyasami, V. et al., Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J. Diabetes 2009, 1, 278-287.
223. Arunkumar, E., Karthik, D., Anuradha, C. V., Genistein sensitizes hepatic insulin signaling and modulates lipid regulatory genes through p70 ribosomal S6 kinase-1 inhibition in high-fat-high-fructose diet-fed mice. Pharm. Biol. 2013, 51, 815-824.
224. Ae, P. S., Choi, M. S., Cho, S. Y., Seo, J. S. et al., Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. Life Sci. 2006, 79, 1207-1213.
225. Lei, H., Lu, F., Dong, H., Xu, L. et al., Genistein reverses free fatty acid-induced insulin resistance in HepG2 hepatocytes through targeting JNK. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2011, 31, 185-189.
226. Shang, J., Chen, L. L., Xiao, F. X., Sun, H. et al., Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29, 698-706.
227. Jeon, B. T., Jeong, E. A., Shin, H. J., Lee, Y. et al., Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012, 61, 1444-1454.
228. Cho, I. J., Ahn, J. Y., Kim, S., Choi, M. S. et al., Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 2008, 367, 190-194.
229. Gomez-Zorita, S., Fernandez-Quintela, A., Macarulla, M. T., Aguirre, L. et al., Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr. 2012, 107, 202-210.
230. Alberdi, G., Rodriguez, V. M., Macarulla, M. T., Miranda, J. et al., Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition 2013, 29, 562-567.
231. Cho, S. J., Jung, U. J., Choi, M. S., Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br. J. Nutr. 2012, 108, 2166-2175.
232. Ahn, J., Cho, I., Kim, S., Kwon, D. et al., Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J. Hepatol. 2008, 49, 1019-1028.
233. Poulsen, M. M., Larsen, J. O., Hamilton-Dutoit, S., Clasen, B. F. et al., Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr. Res. 2012, 32, 701-708.
234. Bagul, P. K., Middela, H., Matapally, S., Padiya, R. et al., Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol. Res. 2012, 66, 260-268.
235. Bujanda, L., Hijona, E., Larzabal, M., Beraza, M. et al., Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008, 8, 40.
236. Kang, W., Hong, H. J., Guan, J., Kim, D. G. et al., Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012, 61, 424-433.
237. Chen, S., Li, J., Zhang, Z., Li, W. et al., Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Can. J. Physiol. Pharmacol. 2012, 90, 237-242.
238. Wang, G. L., Fu, Y. C., Xu, W. C., Feng, Y. Q. et al., Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem. Biophys. Res. Commun. 2009, 380, 644-649.
239. Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K. et al., SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 2008, 283, 20015-20026.
240. Jung, T. W., Lee, K. T., Lee, M. W., Ka, K. H., SIRT1 attenuates palmitate-induced endoplasmic reticulum stress and insulin resistance in HepG2 cells via induction of oxygen-regulated protein 150. Biochem. Biophys. Res. Commun. 2012, 422, 229-232.
241. Shapiro, H., Bruck, R., Therapeutic potential of curcumin in non-alcoholic steatohepatitis. Nutr. Res. Rev. 2005, 18, 212-221.
242. Kuo, J. J., Chang, H. H., Tsai, T. H., Lee, T. Y., Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis. Int. J. Mol. Med. 2012, 30, 673-679.
243. Zeng, C. H., Zeng, P., Deng, Y. H., Shen, N. et al., The effects of curcumin derivative on experimental steatohepatitis. Zhonghua Gan. Zang. Bing. Za Zhi 2011, 19, 454-459.
244. Weisberg, S. P., Leibel, R., Tortoriello, D. V., Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149, 3549-3558.
245. Ramirez-Tortosa, M. C., Ramirez-Tortosa, C. L., Mesa, M. D., Granados, S. et al., Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic. Biol. Med. 2009, 47, 924-931.
246. Qu, X. B., Zhao, S. P., Xu, J., Dong, L. N., Effects of curcumin on secretion of adiponectin and interleukin-6 in human adipose tissues: an in vitro study. Zhong. Xi. Yi. Jie. He. Xue. Bao. 2008, 6, 711-715.
247. Mouzaoui, S., Rahim, I., Djerdjouri, B., Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-alpha-induced oxidative stress, colitis and hepatotoxicity in mice. Int. Immunopharmacol. 2012, 12, 302-311.
248. Kuo, J. J., Chang, H. H., Tsai, T. H., Lee, T. Y., Curcumin ameliorates mitochondrial dysfunction associated with inhibition of gluconeogenesis in free fatty acid-mediated hepatic lipoapoptosis. Int. J. Mol. Med. 2012, 30, 643-649.
249. Messner, D. J., Rhieu, B. H., Kowdley, K. V., Iron overload causes oxidative stress and impaired insulin signaling in AML-12 hepatocytes. Dig. Dis. Sci. 2013, 58, 1899-1908.
250. Lin, J., Zheng, S., Chen, A., Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. Lab. Invest. 2009, 89, 1397-1409.
251. Lin, J., Chen, A., Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2. Mol. Cell. Endocrinol. 2011, 333, 160-171.
252. Tang, Y., Chen, A., Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase. Br. J. Pharmacol. 2010, 161, 1137-1149.
253. Tang, Y., Chen, A., Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids. Endocrinology 2010, 151, 4168-4177.
254. Kang, Q., Chen, A., Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab. Invest. 2009, 89, 1275-1290.
255. Kang, Q., Chen, A., Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br. J. Pharmacol. 2009, 157, 1354-1367.
256. Garcea, G., Jones, D. J., Singh, R., Dennison, A. R. et al., Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 2004, 90, 1011-1015.